Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00651300




Registration number
NCT00651300
Ethics application status
Date submitted
31/03/2008
Date registered
2/04/2008
Date last updated
11/06/2009

Titles & IDs
Public title
A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery
Scientific title
A Multicentre, Double-Blind, Placebo-Controlled Study of the Recovery Benefits Following Treatment With a Cox-2 Regimen in Patients Undergoing Elective Laparoscopic Intra-Peritoneal Abdominal Surgery
Secondary ID [1] 0 0
A3481026
Secondary ID [2] 0 0
PARA-0505-086
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pain 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Parecoxib/Valdecoxib
Treatment: Drugs - Placebo

Experimental: Group 1 -

Placebo comparator: Group 2 -


Treatment: Drugs: Parecoxib/Valdecoxib
A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3

Treatment: Drugs: Placebo
A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Total intake of morphine in first 4 hours post-surgery upon waking of patients receiving parecoxib versus control group.
Timepoint [1] 0 0
4 hours
Secondary outcome [1] 0 0
Evaluation of unplanned hospital admissions on Day 4.
Timepoint [1] 0 0
4 days
Secondary outcome [2] 0 0
Health Outcomes Recovery Questionnaire on Days 2, 3, and 4.
Timepoint [2] 0 0
4 days
Secondary outcome [3] 0 0
Collection of adverse events immediately before surgery, 1 and 6 hours after surgery, and on Days 2, 3, and 4.
Timepoint [3] 0 0
4 days
Secondary outcome [4] 0 0
Length of stay on Day 1.
Timepoint [4] 0 0
1 day
Secondary outcome [5] 0 0
Patient Satisfaction Questionnaire on Days 1 and 4.
Timepoint [5] 0 0
4 days
Secondary outcome [6] 0 0
Quality of Recovery Score on Days 1, 2, and 3.
Timepoint [6] 0 0
3 days
Secondary outcome [7] 0 0
Numerical Rating Scale on Days 1 (hourly for 6 hours), 2, 3, and 4.
Timepoint [7] 0 0
4 days
Secondary outcome [8] 0 0
Modified Brief Pain Inventory on Days 2, 3, and 4.
Timepoint [8] 0 0
4 days
Secondary outcome [9] 0 0
Readiness for discharge on Day 1.
Timepoint [9] 0 0
1 day

Eligibility
Key inclusion criteria
* Male or female aged 18 to 65 years weighing at least 50 kg but no more than 110 kg undergoing elective intra-peritoneal laparoscopic abdominal surgery
* American Society of Anaesthesiologists (ASA) Physical Status I-III
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Significant chronic disease, such as renal, hepatic, cardiovascular, or respiratory, which would contraindicate participation in the study or interfere with interpretation of study results
* Active gastrointestinal disease, chronic or acute renal or hepatic disorder, or known coagulation defect

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2004
Sample size
Target
Accrual to date
Final
91
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Port Macquarie
Recruitment hospital [2] 0 0
Pfizer Investigational Site - Randwick
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Westmead
Recruitment hospital [4] 0 0
Pfizer Investigational Site - Coopers Plain
Recruitment hospital [5] 0 0
Pfizer Investigational Site - Townsville
Recruitment hospital [6] 0 0
Pfizer Investigational Site - Heidelberg
Recruitment hospital [7] 0 0
Pfizer Investigational Site - Prahran
Recruitment hospital [8] 0 0
Pfizer Investigational Site - Perth
Recruitment postcode(s) [1] 0 0
- Port Macquarie
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4108 - Coopers Plain
Recruitment postcode(s) [5] 0 0
4814 - Townsville
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
3181 - Prahran
Recruitment postcode(s) [8] 0 0
6847 - Perth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00651300